Evidence map›Paper›PMID 20815659›Full record

ArticleExperimental lung research2010

Regulation of cytokine-induced prostanoid and nitric oxide synthesis by extracellular signal–regulated kinase 1/2 in lung epithelial cells.

Pamela L Rice, Bradley S Barrett, Jason M Fritz, Mary C Srebernak, Lori R Kisley, Alvin M Malkinson, Lori D Dwyer-Nield

Open access · greenAbstract read
In one paragraph

Article in Experimental lung research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Pamela L RiceVeterans Affairs Medical Center, Denver, Colorado, USA.
Bradley S Barrett
Jason M Fritz
Mary C Srebernak
Lori R Kisley
Alvin M Malkinson
Lori D Dwyer-Nield
University of Colorado Denver · USUniversity of Colorado Cancer Center · US

Funding

PROMOTION OF LUNG TUMORS BY BHT AND GLUCOCORTICOIDSR01CA033497 · NCI · UNIVERSITY OF COLORADO DENVER · PI MALKINSON, ALVIN M · 1985 to 2008
$3.2M
Chemoprevention of experimental tobacco tumorigenesis.R01CA096310 · NCI · UNIVERSITY OF LOUISVILLE · PI GUPTA, RAMESH C · 2002 to 2004
$1.8M
Lung tumor associated macrophagesR01CA132552 · NCI · UNIVERSITY OF COLORADO DENVER · PI NIELD, LORI DWYER · 2008 to 2012
$1.4M
NCI NIH HHS CA132552NCI NIH HHS CA33497NCI NIH HHS CA96310NCI NIH HHS R01 CA033497NCI NIH HHS R01 CA096310NCI NIH HHS R01 CA132552
6 · The paper itself

Abstract

The inflammatory cytokines tumor necrosis factor alpha (TNFα) and interferon gamma (IFNγ) stimulate production of the inflammatory mediators prostaglandin E₂ (PGEγ), prostacyclin (PGIγ), and nitric oxide (NO) in cultured lung epithelial cells. Pretreatment of these cells with the selective MEK1/2 (mitogen-activated protein kinase/extracellular signal-regulated kinase [ERK] kinase 1/2) inhibitor U0126 blocked ERK1/2 activation and inhibited cytokine-induced production of these inflammatory mediators. Primary bronchiolar epithelial Clara cells treated with TNFα and IFNγ also produced increased PGE₂, PGI₂, and NO, and PG and NO production was decreased by MEK inhibition. U0126 differentially affected cyclooxygenase (COX)-1, COX-2, and inducible NO synthase (iNOS) expression in cell lines, however, suggesting that MEK1/2 regulates prostanoid and NO production by means other than inducing their biosynthetic enzymes. Functionally, inhibition of MEK1/2 caused G1 cell cycle arrest and decreased cyclin D1 expression, but these effects were not related to decreased prostanoid production. These results indicate separate proinflammatory and proliferative roles for ERK1/2 in lung epithelial cells. During lung tumor formation in vivo, ERK1/2 phosphorylation increased as lung tumors progressed. Since tumor-derived cells were more sensitive than nontumorigenic cells to the antiproliferative effects of U0126, MEK1/2 inhibition may serve as an attractive chemotherapeutic target.

Indexed as

AnimalsApoptosisBlotting, WesternButadienesCell Line, TumorCell ProliferationEnzyme InhibitorsExtracellular Signal-Regulated MAP KinasesInterferon-gammaLungLung NeoplasmsMaleMiceMice, Inbred BALB CMice, Inbred StrainsNitric OxideButadienesEnzyme InhibitorsExtracellular Signal-Regulated MAP KinasesInterferon-gammaNitric OxideNitrilesProstaglandinsTumor Necrosis Factor-alphaU 0126

Identifiers

PMID20815659
PMCPMC3084151
OpenAlexW2048347722

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.